Glaxo's flu treatment approved in US
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.GLAXO WELLCOME, the pounds 58bn pharmaceuticals company, has received regulatory approval in the United States for a revolutionary flu treatment. Analysts expect Relenza, which is administered by inhaler, to generate annual sales of at least pounds 300m by 2003.
Glaxo has licensed the treatment from Biota, an Australian biotechnology company, which is to receive a 7 per cent cut of Relenza's sales.
The drug is already on the market in Australia and New Zealand, and has been approved in all of the countries of the European Union. It will be launched in the US and UK this autumn. Glaxo's costs in taking the treatment through clinical trials are thought to have totalled pounds 400m.
Relenza works by attempting to arrest the flu virus, which resides in the throat and lungs, at source. It prevents it spreading from one cell to another within the respiratory tract. In clinical trials, flu patients on Relenza suffered less severe symptoms and recovered faster than those on a placebo drug. Glaxo shares yesterday closed up 73p at 1679p.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments